ADA Linagliptin in Long Term Care

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT02061969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02061969
Other papers using this trial's data
  • A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial Journal of the American Medical Directors Association, 2018-05 DOI, PubMed 29289540, PMC6093296 PubMed links an erratum for this paper. Erratum: PMID 31147287 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02061969. Randomized; no masking; primary purpose treatment. Start 2014-04-25 (registry gives no type); primary completion 2017-04-10 (actual). Results posted on 2018-08-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ADA Linagliptin in Long Term Care
Condition
Diabetes
Intervention (Drug)
linagliptin
Intervention (Drug)
insulin glargine
Lead sponsor
Emory University (class: other)
Collaborator
American Diabetes Association (class: other)

Record details

Record id
cardio:ct-nct02061969
Content hash
1cd02f99eade219010382025e289e9a88166158acfb301bf67e05fe086605491